- Home
- SKIN vs BDTX Comparison
SKIN vs BDTX Comparison
Compare SKIN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIN | BDTX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.7M | 220.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKIN | BDTX |
|---|---|---|
| Price | $1.49 | $2.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.42 | ★ $10.60 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $301,917,000.00 | $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.30 | N/A |
| P/E Ratio | ★ N/A | $7.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $1.20 |
| 52 Week High | $2.69 | $4.94 |
Technical Indicators
Market Signals| Indicator | SKIN | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 26.33 |
| Support Level | $1.36 | $2.24 |
| Resistance Level | $1.35 | $3.90 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 55.42 | 20.97 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.